Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Muriel Velez, Bryan Nicolalde, Kevin Moreno-Montenegro, Gabriela Carolina Carrera-Barriga, Camila Gallegos and Beatriz Leon, Universidad San Francisco de Quito, Quito, Ecuador
Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…
Abstract Number: 010 • 2023 Pediatric Rheumatology Symposium
Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation
Natoshia Cunningham¹, Michelle Adler², Ashley Danguecan³, Mallet Reid², Samantha Ely⁴, Mathew Reeves², Lawrence Ng³, Paris Moaf³, Sarah Mossad³, Tala El Tal³, Luana Flores Pereira³, Deborah Levy³, Linda Hiraki³, Jennifer Stinson³, Sarah Ahola Kohut³, Khalid Abulaban⁵, Elizabeth Kessler⁵, Stacy Allen⁵, Tamar Rubinstein⁶, Evin Rothschild⁶, Natalie Rosenwasser⁷, Kabita Nanda⁷, Susan Canny⁷, Emily Smitherman⁸, Livie Huie⁸, James Birmingham⁹, Allison Thompson¹⁰, Janel Thompson¹⁰, Miranda Moyer¹⁰, Emily Nguyen¹⁰, Angela Chapson¹⁰ and Andrea Knight³, ¹Michigan State University, Grand Rapids, MI, ²Michigan State University, East Lansing, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Wayne State University, Michigan State University, Detroit, MI, ⁵Helen DeVos Children's Hospital, Grand Rapids, MI, ⁶Children's Hospital at Montefiore, New York, NY, ⁷Seattle Children's Hospital, Seattle, WA, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Metro Health, Cleveland, ¹⁰Patient Co-Investigative Team
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is associated with fatigue, pain, and depressive symptoms that adversely impact health-related quality of life. The Treatment and Education…
Abstract Number: 104 • 2023 Pediatric Rheumatology Symposium
Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)
Oscar Mwizerwa¹, Andrea Knight², Daniela Dominguez², Deborah Levy², Holly Convery², Kendal Thompson², Nicholas Gold², Catharine Walsh² and Linda Hiraki², ¹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) and celiac disease (CD) are autoimmune diseases characterized by the presence of specific autoantibodies. We aimed to investigate the prevalence…
Abstract Number: 011 • 2023 Pediatric Rheumatology Symposium
The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center
Emily Beil¹, Eyal Muscal², Danielle Guffey², Marietta Deguzman¹ and Erin Peckham-Gregory², ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Differences in prevalence rates of childhood-onset SLE (cSLE) among different racial/ethnic groups have been well described. Yet, the role of social determinants of health…
Abstract Number: 112 • 2023 Pediatric Rheumatology Symposium
Adverse Childhood Experiences: Prevalence and Relationship to Disease in Childhood-onset Lupus
Olivia Hendrikx¹, Stephanie Fevrier¹, Ibrahim Mohamed¹, Chelsea DeCoste², Paris Moaf¹, Lawrence Ng¹, Deborah Levy¹, Linda Hiraki¹, Alene Toulany¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²IWK Health Centre, Halifax, NS, Canada
Background/Purpose: Adverse Childhood Experiences (ACEs) measure traumatic experiences in childhood. ACEs are associated with epigenetic changes, are known to increase stress response and inflammation, and…
Abstract Number: 012 • 2023 Pediatric Rheumatology Symposium
Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances
Cathy Tsin¹, Megan Troxell¹, Vivek Charu¹, Rufei Lu² and Joyce Hsu³, ¹Stanford University, Palo Alto, CA, ²UCSF, San Francisco, CA, ³Stanford Medicine, Children's Health, Palo Alto, CA
Background/Purpose: Outcomes for pediatric patients with lupus nephritis (LN) remain suboptimal. LN may present with thrombotic microangiopathy (TMA) seen on kidney biopsy. Childhood-onset SLE patients…
Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Yiressy Pina¹, Dawn Janysek¹, Danielle Guffey², Maria Pereira Palacios³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…
Abstract Number: 013 • 2023 Pediatric Rheumatology Symposium
Applying Pathway Analysis to Whole Genome Data to Identify Pathophysiologic Pathways in Childhood-onset Systemic Lupus Erythematosus
Katie Heitzman¹, Luis Franco², Linda Hiraki³, Earl Silverman³, Christiaan Scott⁴, Ana Barrera-Vargas⁵, Zuoming Deng², Mariana Kaplan² and Laura Lewandowski², ¹NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴University of Cape Town, South Africa, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but twin/sibling high concordance rate suggests…
Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Dawn Janysek¹, Yiressy Pina², Danielle Guffey³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
Abstract Number: 014 • 2023 Pediatric Rheumatology Symposium
Characterizing Lupus in African American Children in Southern United States
Anita Dhanrajani¹, Taylor Long¹, Spencer Hagwood², Leslie Johnson¹ and Cynthia Karlson¹, ¹University of Mississipi Medical Center, Jackson, MS, ²University of Mississipi Medical Center School of Medicine, Jackson, MS
Background/Purpose: African-American (AA) ethnicity is a known predisposing factor for childhood onset systemic lupus erythematosus (cSLE) and a predictor of poor outcomes. In addition to…
Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium
Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Lydia Thomas¹, Jenna Battaglia², Bharati Matta³, Kim Simpfendorfer⁴, Joyce Hui-Yuen⁵ and Betsy Barnes³, ¹Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, ²Northwell Health, New York, NY, ³Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁵Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…
Abstract Number: L07 • ACR Convergence 2022
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Di Wu¹, Jing Li¹, Dong Xu¹, Li Wang¹, Jianmin Fang², Dan Ross³ and Fengchun Zhang⁴, ¹Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, ²Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, ³RemeGen Co., San Diego, CA, ⁴Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China
Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: 0063 • ACR Convergence 2022
Implementability of a SLE Medication Adherence Intervention
Kai Sun¹, Nneka Molokwu², Amy Corneli¹, Kathryn Pollak¹, Alexandria Bennion², Jennifer L Rogers³, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Amanda Eudy⁴, Hayden Bosworth¹ and Megan Clowse², ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC, ⁴Duke University, Raleigh, NC
Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with…
Abstract Number: 0116 • ACR Convergence 2022
Racial Differences in Medication Beliefs and Barriers to Taking Medications Among Patients with SLE
Emilio Guzman Cisneros¹, Shannon Herndon¹, Theresa Coles², Corrine Voils³, Megan Clowse⁴, Rebecca Sadun⁴, Jennifer Rogers⁵, Lisa Criscione-Schreiber², Jayanth Doss⁴, Amanda Eudy⁶ and Kai Sun⁴, ¹Duke University Hospital, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Duke University, Durham, NC, ⁵Duke, Durham, NC, ⁶Duke University, Raleigh, NC
Background/Purpose: Medication adherence is critical for SLE management and can be influenced by patients' barriers and beliefs about treatment. Patients of color with SLE have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].